VerImmune
PrivateLast Round
VC Round
Nov 24, 2025
Total Funding Raised
$6.6M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
VerImmune is a biotechnology company developing a first-in-class cancer immunotherapy known as Anti-tumor Immune Redirection (AIR) that utilizes a proprietary virus-inspired particle technology to redirect pre-existing immune memory to fight cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
VerImmune Comparables
Compare VerImmune with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Valo Therapeutics | 77% | |
| Replimune Group Inc. | 67% | |
| Theriva Biologics | 64% |
VerImmune Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Nov 24, 2025 | ||||
| Grant | Apr 29, 2025 | ||||
| VC Round | Sep 23, 2024 | ||||
| Seed | Sep 20, 2023 | ||||
| Grant | Apr 29, 2023 | ||||
Seed | Jul 27, 2022 |
Key People
Founding team and executive leadership
VerImmune Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Gaingels | Seed, VC Round |
| Mana Ventures | Seed, VC Round |
| TEDCO | VC Round |
| Ulu Ventures | Seed |
| SeedFolio | Seed |
| Proxima Ventures | VC Round |
| Beiley Biofund | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 61% MoM, from 1.1K to 1.8K.
- Nov 24, 2025
$500K round led by TEDCO
VerImmune Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about VerImmune's valuation, stock price, and market status.
Is VerImmune a public or private company?
VerImmune is a private company.
What is the current stock price of VerImmune?
VerImmune is a private company with no public stock price. No recent secondary market data is available.
How much is VerImmune worth (valuation)?
Valuation information for VerImmune is not publicly available.
Can I buy VerImmune stock?
VerImmune shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was VerImmune's last funding round?
VerImmune's most recent funding round was Seed on September 23, 2024.
Who are the main investors in VerImmune?
Key investors in VerImmune include SeedFolio, Beiley Biofund.
Will VerImmune IPO soon?
No public IPO plans have been announced for VerImmune.
How can I track VerImmune secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor VerImmune's secondary market activity and sign up for updates.